Great post Mr. JD beenthere wrote:
Reminds all us Oldtimers just how we got sucked into this for all these years!
That's beenthere reminding us all that he feels he has been VICTIMIZED by JD and blames JD for his own investment in Bioasis.
That's weak man… or maybe just a weak man who blames others for their own actions? Either/or, you’re a weak man, beenthere. You continue to exhibit some of the poorest qualities of human behaviour – anger and hate.
beenthere, if you did invest in Bioasis because of JD, it's because what he's written over the years makes a whole lot of sense the great majority of the time. His predictions (ours as well) didn’t always come true but the verdict is not yet in.
xB3 has not yet failed and has the strong possibility of curing brain cancer which is worth more than a billion dollars imo. $0.17 a share? I wish I could laugh but $0.17 is a joke. The market doesn't know jack other than the time is not yet here, but reading between the lines certainly suggests something is up. Bring it on DrDR.
So, beenthere, I guess if Bioasis hits the bigtime, you’ll thank JD and apologise to him for you being such a baby all these years? That’s a laugher but you wouldn’t get it, just like you seem to forget about why you placed your bet on Bioasis.
I’m going to repost JD’s excellent post from earlier today. Concise, true, and easy to understand (even for beenthere).
FYI - JD was a strong supporter and believer in Bioasis long before they started issuing him checks. I’ve said it before and I’ll say it again, the guy is a warrior, and a f’n smart one. Thanks for another great post today, JD. A well deserved 10 thumbs up!
JD wrote:
It's a good question, minedigger, "So why did JCR buy ArmaGen and not Bioasis?"
I'll get to that but here's a better question.
Why didn't Shire buy ArmaGen? After all, Shire entered a
development deal with Shire in July 2014 to develop AGT-182. The deal included cash an an EQUITY POSITION in ArmaGen. (Shire owned a piece of ArmaGen and still let JCR buy it!)
Shire would know all there is to know about ArmaGen and Shire took a pass. If you do a search for ArmaGen, AGT-181, or AGT-182 on the clnicaltrials.gov website you will find part of the answer. Those trials had their final commentaries from ArmaGen in 2018 with no results posted. None! The trials, 5 of them, all Phase 1 dosing studies, are marked complete but no results were posted for any of them.
It doesn't sound like ArmaGen had anything to brag about, does it? (If Shire liked the results, Shire would have pressed ArmaGen to advance on to Phase 2, I imagine.)
Meanwhile, the Japanese powerhouse, Takeda, buys Shire and then buys a piece of Denali, another erstwhile Bioasis competitor. The Takeda/Shire combo wasn't interested in ArmaGen.
You know what I think might have happened? Another Japanese company, JCR Pharmaceuticals, decided to get into the BBB game, maybe to create some "we're in the BBB business, too" optics for themselves. But JCR had to take the leftovers, ArmaGen. ArmaGen remains a wholey-owned subsidiary of JCR. Maybe there's some IP in ArmaGen that JCR thinks will be useful. Maybe it's all optics. Maybe JCR will fund a Phase 2 trial on AGT-182. But the news on that front could likely be more BBB-related than MPS II-related. Doing anything in the human brain would make news. JCR knows that. Denali will likely have some positive results. So may JCR. JCR, Takeda and Denali may all see their share prices spike as a result. Maybe that's what JCR is looking for.
But in the end, ArmaGen has done nothing that impresses. Was the sale of ArmaGen to JCR actually a fire sale? Very possible.
So "So why did JCR buy ArmaGen and not Bioasis?"
First of all, I confess, I didn't know Bioasis was, or is, for sale. We're going after big fish, brain tumours, and we're likely to be successful with that. Also, we have a high likelihood of completing deals that could very well dwarf this JCR/ArmaGen deal. (Think about that for a moment.)
xB3 completely outperforms ArmaGen's technology. We don't use a receptor that is a threat to the whole body like insulin can be. xB3 outperforms Denali's F-Star offering. xB3 delivers to the brain up to 4 times as much drug as Denali can do, which means we can administer 75% less drug and still get as much into the brain as Denali. We don't need to rehash the comparisons, again, here.
Over the years there have been rumours of "talks" and "enquiries" between large pharmas and Bioasis about whether Bioasis is for sale. Those "talks," if they happened, clearly didn't go anywhere. Whatever mistakes that Bioasis boards and managements have made over the years, they all knew the potential value of xB3.
They knew, as we all still know, that we have a billion dollar drug on our hands with xB3-001 if it can successfully treat HER2+ brain tumours. They, and we, also know that success with xB3-001 will punch the value of our entire pipeline and the value of xB3 as a platform.
Why would any self-respecting management sell the company for a buck when there is such a big win on the table?
And if a management team did recommend a sellout at anything less that at least a few dollars, would shareholders vote for that? The management would have to make it clear to shareholders that xB3 does not have sufficient value, or represents too much of a risk, and therefore the company should be sold. Are there any grounds for management to say these things?
But, everything has a price, including Bioasis. I don't know how low of a price Bioasis shareholders would be willing to sell at. Right now, there are those who would throw in the towel at less than a buck, maybe 50¢. (Some people sold at 16¢ recently.) Their opinion might change if we get a BD deal or two. Their opinions are even more likely change as we get nearer to Phase 1b/2 with xB3-001. Their opinions will change if we can get to a buck, or two bucks.
I don't think we'll get to those share prices without first making some news. "Earned" media coverage will put Bioasis in front of millions of investors. I've always suggested to those who want to sell the company that they can sell their shares at $1, $2, $4 or $6, as the rest of us go for the breathtaking values that a universal carrier and the pipeline it spawned should realize.
jdstox